Certara, Inc. (NASDAQ:CERT) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 473.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,172 shares of the company’s stock after acquiring an additional 22,430 shares during the period. Tower Research Capital LLC TRC’s holdings in Certara were worth $289,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. First Trust Advisors LP bought a new stake in shares of Certara during the fourth quarter valued at about $140,000. Marshall Wace LLP raised its position in shares of Certara by 11.3% during the 4th quarter. Marshall Wace LLP now owns 47,855 shares of the company’s stock worth $510,000 after buying an additional 4,855 shares in the last quarter. Gamco Investors INC. ET AL bought a new position in shares of Certara in the fourth quarter valued at approximately $133,000. XTX Topco Ltd increased its stake in shares of Certara by 202.2% during the fourth quarter. XTX Topco Ltd now owns 31,342 shares of the company’s stock valued at $334,000 after acquiring an additional 20,970 shares during the period. Finally, Mariner LLC raised its holdings in Certara by 26.5% during the fourth quarter. Mariner LLC now owns 23,823 shares of the company’s stock worth $254,000 after purchasing an additional 4,991 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of CERT opened at $12.99 on Friday. Certara, Inc. has a one year low of $8.64 and a one year high of $17.94. The company has a 50-day moving average of $11.70 and a two-hundred day moving average of $11.65. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -64.95, a PEG ratio of 9.29 and a beta of 1.64.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CERT. KeyCorp increased their price target on Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, April 16th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Barclays cut their price target on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Robert W. Baird lifted their price objective on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. Finally, Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.17.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.